RUXIENCE

Concentrate for solution for infusion, 100mg
RxActive license

Active substance (INN)

rituximab

Pharmaceutical form

Pharmaceutical formConcentrate for solution for infusion
Strength100mg
PackagingUkupno 1 bočica staklena sa 10ml koncentrata za rastvor za infuziju u kartonskoj kutiji
ManufacturerPfizer Manufacturing Belgium NV, Belgium
Therapeutic groupAntineoplastic and immunomodulating agents (L01FA01)
Marketing authorization holder"EVROPA LEK PHARMA" DOO PODGORICA
Authorization dateDecember 12, 2022

Analogs in Montenegro

7

Other medicines with the same active substance

MABTHERARx
Solution for injection, 1400mg/11.7mlF. Hoffmann-La Roche AG
MABTHERARx
Solution for injection, 1600mg/13.4mlF. Hoffmann-La Roche AG
MABTHERARx
Concentrate for solution for infusion, 500mg/50mlF.Hoffmann-La Roche Ltd.
MABTHERARx
Concentrate for solution for infusion, 100mg/10mlF.Hoffmann-La Roche Ltd.
RIXATHONRx
Concentrate for solution for infusion, 100mg/10mlSandoz GmbH Schaftenau
RIXATHONRx
Concentrate for solution for infusion, 500mg/50mlSandoz GmbH Schaftenau
RUXIENCERx
Concentrate for solution for infusion, 500mgPfizer Manufacturing Belgium NV
Source: CInMED register